BIOMAT Database Logo BIOMAT Database Logo

Adjuvant immunotherapy using fibroblasts genetically engineered to secrete interleukin 12 prevents recurrence after surgical resection of established tumors in a murine adenocarcinoma model. 1999

G Matsumoto, and M Sunamura, and H Shimamura, and T Kodama, and W Hashimoto, and M Kobari, and K Kato, and K Takeda, and H Yagita, and K Okumura, and H Hamada, and S Matsuno
First Department of Surgery, Tohoku University School of Medicine, Sendai, Japan.

BACKGROUND To explore effective therapeutic strategy against cancer of the gastrointestinal tract, tumor vaccination using fibroblasts secreting interleukin-12 (IL-12) was developed as an adjuvant therapy against murine tumor after surgical resection. METHODS Initially, IL-12 was genetically engineered into fibroblasts (IL-12/3T3 cells), and then we evaluated in vivo and in vitro antitumor effects. In the vaccination model, irradiated C-26 tumor mass was reinoculated intradermally with IL-12/3T3 cells in mice as a tumor vaccine to examine how much it suppresses tumor recurrence. RESULTS IL-12/3T3 cells producing 7.2 ng/10(6) cells/24 h murine IL-12 in vitro exerted dose-dependent potent tumor suppression when coinoculated with C-26 cells in vivo. Specific immunity was also acquired in 63% of mice in vivo. In the vaccination model, protective immunity was developed in 70% of mice that were inoculated with irradiated tumor mass and IL-12/3T3 cells. In addition, local recurrence was not observed in vaccinated mice, although 44% of control mice had recurrence. CONCLUSIONS Coinoculation of genetically engineered fibroblasts secreting IL-12 with irradiated tumor mass was proved to be an effective tumor vaccine. This system of vaccination is easily applicable to clinical situations, particularly to human gastrointestinal tract cancers.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D005822 Genetic Vectors DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition. Cloning Vectors,Shuttle Vectors,Vectors, Genetic,Cloning Vector,Genetic Vector,Shuttle Vector,Vector, Cloning,Vector, Genetic,Vector, Shuttle,Vectors, Cloning,Vectors, Shuttle

Related Publications

G Matsumoto, and M Sunamura, and H Shimamura, and T Kodama, and W Hashimoto, and M Kobari, and K Kato, and K Takeda, and H Yagita, and K Okumura, and H Hamada, and S Matsuno
Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts.
August 1995, Journal of immunology (Baltimore, Md. : 1950),
G Matsumoto, and M Sunamura, and H Shimamura, and T Kodama, and W Hashimoto, and M Kobari, and K Kato, and K Takeda, and H Yagita, and K Okumura, and H Hamada, and S Matsuno
Gene therapy for murine renal cell carcinoma using genetically engineered tumor cells to secrete interleukin-12.
March 2000, Hiroshima journal of medical sciences,
G Matsumoto, and M Sunamura, and H Shimamura, and T Kodama, and W Hashimoto, and M Kobari, and K Kato, and K Takeda, and H Yagita, and K Okumura, and H Hamada, and S Matsuno
Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.
January 1994, Cancer research,
G Matsumoto, and M Sunamura, and H Shimamura, and T Kodama, and W Hashimoto, and M Kobari, and K Kato, and K Takeda, and H Yagita, and K Okumura, and H Hamada, and S Matsuno
Improved survival with adjuvant immunotherapy after surgical resection in a murine model.
July 1994, Annals of surgical oncology,
G Matsumoto, and M Sunamura, and H Shimamura, and T Kodama, and W Hashimoto, and M Kobari, and K Kato, and K Takeda, and H Yagita, and K Okumura, and H Hamada, and S Matsuno
Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2.
November 1994, Cancer research,
G Matsumoto, and M Sunamura, and H Shimamura, and T Kodama, and W Hashimoto, and M Kobari, and K Kato, and K Takeda, and H Yagita, and K Okumura, and H Hamada, and S Matsuno
Focal Cryo-Immunotherapy with Intratumoral IL-12 Prevents Recurrence of Large Murine Tumors.
April 2023, Cancers,
G Matsumoto, and M Sunamura, and H Shimamura, and T Kodama, and W Hashimoto, and M Kobari, and K Kato, and K Takeda, and H Yagita, and K Okumura, and H Hamada, and S Matsuno
A new model using deep learning to predict recurrence after surgical resection of lung adenocarcinoma.
March 2024, Scientific reports,
G Matsumoto, and M Sunamura, and H Shimamura, and T Kodama, and W Hashimoto, and M Kobari, and K Kato, and K Takeda, and H Yagita, and K Okumura, and H Hamada, and S Matsuno
Suppression of tumor growth and metastasis of murine renal adenocarcinoma by syngeneic fibroblasts genetically engineered to secrete the JE/MCP-1 cytokine.
July 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research,
G Matsumoto, and M Sunamura, and H Shimamura, and T Kodama, and W Hashimoto, and M Kobari, and K Kato, and K Takeda, and H Yagita, and K Okumura, and H Hamada, and S Matsuno
Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo.
March 1995, Neurosurgery,
G Matsumoto, and M Sunamura, and H Shimamura, and T Kodama, and W Hashimoto, and M Kobari, and K Kato, and K Takeda, and H Yagita, and K Okumura, and H Hamada, and S Matsuno
IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts.
December 1995, Human gene therapy,
Copied contents to your clipboard!